aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
November 13 2023 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology
company engaged in the discovery and development of first-in-class
medicines from its proprietary tRNA synthetase platform, today
announced a poster presentation for its lead therapeutic candidate,
efzofitimod, at the American College of Rheumatology (ACR)
Convergence 2023, which is being held November 10 – 15, 2023, in
San Diego, CA.
“These data highlight the broad
anti-inflammatory potential of efzofitimod in treating
immune-driven conditions and strengthen the evidence that
neuropilin-2 (NRP2) is an important immune regulator,” said Sanjay
S. Shukla, M.D., M.S., President and Chief Executive Officer of
aTyr. “Although we remain highly focused on our current clinical
development program for efzofitimod in interstitial lung disease
(ILD), which includes pulmonary sarcoidosis and systemic sclerosis
(SSc or scleroderma)-related ILD, this data provides further
evidence regarding the potential broader application of efzofitimod
in inflammatory diseases beyond these respiratory conditions.”
Details of the presentation appear below. The
poster will be available on the aTyr website once presented.
Title: Efzofitimod, a First-in-Class
NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis
and Associated Lung Fibrosis in Preclinical ModelsSession
Title: RA – Treatment Poster IISession
Format: Poster PresentationPoster Number:
1322Date and Time: Monday, November 13, 2023, from
9:00 a.m. to 11:00 a.m. PSTLocation: Poster Hall,
San Diego Convention Center
The poster presents findings from preclinical
models of rheumatoid arthritis (RA) and RA-associated ILD (RA-ILD),
where NRP2, efzofitimod’s binding partner, is known to be expressed
on pro-inflammatory synovial macrophages. An animal knockout model
for NRP2 demonstrated that NRP2 deficiency exacerbated disease
pathology in preclinical models of inflammatory disease. In a model
of collagen-induced RA, efzofitimod treatment lowered disease
severity and improved remission. Furthermore, in a transgenic mouse
model for RA-ILD, treatment with efzofitimod led to a reduction in
the number of pro-inflammatory immune cell populations in the lungs
and exhibited a noteworthy reduction in RA-induced lung fibrosis.
The data indicate a critical role for NRP2 in modulating immune
responses and suggest the potential of efzofitimod as a therapeutic
intervention for RA-ILD and potentially other immune-mediated
diseases.
About
Efzofitimod
Efzofitimod is a first-in-class biologic
immunomodulator in clinical development for the treatment of
interstitial lung disease (ILD), a group of immune-mediated
disorders that can cause inflammation and fibrosis, or scarring, of
the lungs. Efzofitimod is a tRNA synthetase derived therapy that
selectively modulates activated myeloid cells through neuropilin-2
to resolve inflammation without immune suppression and potentially
prevent the progression of fibrosis. aTyr is currently
investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in
patients with pulmonary sarcoidosis, a major form of ILD, and in
the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis
(SSc, or scleroderma)-related ILD. These forms of ILD have limited
therapeutic options and there is a need for safer and more
effective, disease-modifying treatments that improve outcomes.
About aTyr
aTyr is a clinical stage biotechnology company
leveraging evolutionary intelligence to translate tRNA synthetase
biology into new therapies for fibrosis and inflammation. tRNA
synthetases are ancient, essential proteins that have evolved novel
domains that regulate diverse pathways extracellularly in humans.
aTyr’s discovery platform is focused on unlocking hidden
therapeutic intervention points by uncovering signaling pathways
driven by its proprietary library of domains derived from all 20
tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod,
a first-in-class biologic immunomodulator in clinical development
for the treatment of interstitial lung disease, a group of
immune-mediated disorders that can cause inflammation and
progressive fibrosis, or scarring, of the lungs. For more
information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “believes,” “can,”
“expects,” “intends,” “may,” “plans,” “potential,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements include, among others,
statements regarding the potential of efzofitimod to improve
disease outcomes and mitigate fibrosis in preclinical models of RA
and RA-ILD; the potential to be a therapeutic intervention for RA,
RA-ILD and other immune-mediated diseases; and the potential
applications of efzofitimod. These forward-looking statements also
reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects, as reflected in or suggested by these
forward-looking statements, are reasonable, we can give no
assurance that the plans, intentions, expectations, strategies or
prospects will be attained or achieved. All forward-looking
statements are based on estimates and assumptions by our management
that, although we believe to be reasonable, are inherently
uncertain. Furthermore, actual results may differ materially from
those described in these forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, uncertainty regarding
geopolitical and macroeconomic events, risks associated with the
discovery, development and regulation of efzofitimod, the risk that
we or our partners may cease or delay preclinical or clinical
development activities for efzofitimod for a variety of reasons
(including difficulties or delays in patient enrollment in planned
clinical trials), the possibility that existing collaborations
could be terminated early, and the risk that we may not be able to
raise the additional funding required for our business and product
development plans, as well as those risks set forth in our most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and in our other SEC filings. Except as required by law, we assume
no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
|
|
Contact: |
|
Ashlee Dunston |
|
Director, Investor Relations and
Public Affairs |
|
adunston@atyrpharma.com |
|
|
|
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024